Tagged with HKU-CTC

Hong Kong Hong Kong has grand plans to become one of Asia’s leading clinical trial hubs. Important regulatory upgrades and increased integration with mainland China via the Greater Bay Area initiative – including a new dedicated GBA Clinical Trial Institute at the Hong Kong/mainland border – mean that this is not just…

Hong Kong Hong Kong needs to capitalise on its strong fundamentals to establish itself as a clinical research hotspot within APAC and support its transition into China’s innovation and technology hub. Does a new one-stop-shop for clinical trials across the Greater Bay Area hold the key?   Clinical trial numbers are skyrocketing…

Hong Kong Hong Kong provides some of the best and most efficient healthcare in Asia, with Hong Kongers living to over 85 on average (compared to 83 in Singapore and 78 in mainland China), and the World Health Organisation ranks the city among the top 20 healthcare systems globally. However, unlike many…

Hong Kong Almost a decade on from the establishment of a Phase I clinical trial centre in Hong Kong, the city continues to pursue a stronger positioning within the global clinical research landscape. Strengthened by its experience in conducting COVID-19 vaccine trials, the global trends towards clinical research in Asia and more…

Hong Kong Small markets must inevitably etch out a niche positioning for themselves, and for Hong Kong, its world-class medical infrastructure, world-renowned academics and clinicians as well as high population density make it a strong contender in clinical research.   Hong Kong is an important piece of our global R&D landscape Scott…

Hong Kong Henry Yau, MD and Honorary Assistant Professor at the University of Hong Kong Clinical Trials Centre (HKU-CTC) discusses the center’s development, the diverse range of services it offers, and the clinical trials environment in Hong Kong. Having been with the organization since nearly the beginning from 2000, how have you…